| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥11.86 |
| 52 Week High | CN¥23.20 |
| 52 Week Low | CN¥11.32 |
| Beta | 0.67 |
| 1 Month Change | -10.42% |
| 3 Month Change | -20.08% |
| 1 Year Change | -46.82% |
| 3 Year Change | -73.26% |
| 5 Year Change | -55.99% |
| Change since IPO | 9.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2196 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 3.0% | 1.8% | 2.3% |
| 1Y | -46.8% | -17.4% | -10.9% |
Return vs Industry: 2196 underperformed the Hong Kong Pharmaceuticals industry which returned -17.4% over the past year.
Return vs Market: 2196 underperformed the Hong Kong Market which returned -10.9% over the past year.
Price Volatility
| 2196 volatility | |
|---|---|
| 2196 Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.5% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2196's share price has been volatile over the past 3 months.
Volatility Over Time: 2196's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 40,370 | Deyong Wen | www.fosunpharma.com |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Fundamentals Summary
| 2196 fundamental statistics | |
|---|---|
| Market cap | HK$58.64b |
| Earnings (TTM) | HK$2.58b |
| Revenue (TTM) | HK$44.75b |
25.5x
P/E Ratio1.5x
P/S RatioIs 2196 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2196 income statement (TTM) | |
|---|---|
| Revenue | CN¥41.40b |
| Cost of Revenue | CN¥21.72b |
| Gross Profit | CN¥19.68b |
| Other Expenses | CN¥17.30b |
| Earnings | CN¥2.39b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | 0.89 |
| Gross Margin | 47.54% |
| Net Profit Margin | 5.76% |
| Debt/Equity Ratio | 57.7% |
How did 2196 perform over the long term?
See historical performance and comparison